Amyloid tumour
Imaging findings in relapsing multiple myeloma
Prognostic factors in adult acute lymphoblastic leukaemia
Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection
Plasma cell leukaemia and other aggressive plasma cell malignancies
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
Evidence for a common genetic aetiology in high-risk families with multiple haematological malignancy subtypes
Specific effects exerted by B-lymphoproliferative diseases on peripheral T-lymphocyte protein expression
Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk
Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia
A severe case of warfarin–canrenoate interaction: a role for genetic predisposition?
Paroxysmal nocturnal haemoglobinuria clones in children with acquired aplastic anaemia: a prospective single centre study
Age-related complications in treatment-naïve patients with thalassaemia intermedia
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. Response to Kontoghiorghes et al
Thrombophilic screening in patients with paroxysmal nocturnal haemoglobinuria: a pilot study
The myths about platelet transfusions in immune-mediated thrombocytopenias
Thromboembolic events are not uncommon in patients with immune thrombocytopenia